Clinical Trial Update: Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002 [Phase 1]

View source ↗

Summary

Phase 1 single radiolabeled dose study to characterize absorption, metabolism, and excretion of [14C]-ETC-1002. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• ETC-1002 (bempedoic acid)

Snippet

Sponsor: Esperion Therapeutics, Inc. | Conditions: Hyperlipidemia | Phase 1 | Status: COMPLETED